Rituximab in chronic lymphocytic leukemia.

Abstract

Rituximab (Rituxan; iogen Idec, San Diego, CA, USA) is a human-mouse chimeric monoclonal antibody specific for CD20, a surface glycoprotein expressed on B lymphocytes. Administration of rituximab as a single agent to patients with chronic lymphocytic leukemia (CLL) has limited clinical activity, but generally does not eradicate leukemia from the marrow… (More)
DOI: 10.1007/s12325-011-0032-2

Topics

  • Presentations referencing similar topics